Genesis of an IPO ... from NO

EDITOR'S NOTE: Carl Djerassi's novel NO concerns the development of a fictional, though close-to-life, drug and delivery system for the relief of male impotence. While the science in the novel is accurate, the book is a work of fiction. Nevertheless, some real-life characters, including Djerassi himself (a professor in the chemistry department at Stanford University), and other more or less disguised fictional characters based on real people make appearances in the book. In this issue and in t

| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

EDITOR'S NOTE: Carl Djerassi's novel NO concerns the development of a fictional, though close-to-life, drug and delivery system for the relief of male impotence. While the science in the novel is accurate, the book is a work of fiction. Nevertheless, some real-life characters, including Djerassi himself (a professor in the chemistry department at Stanford University), and other more or less disguised fictional characters based on real people make appearances in the book. In this issue and in the upcoming October 26 issue, we are publishing Chapter 19. In this extract we meet the chief protagonist of the book, an Indian scientist named Renu Krishnan, who has developed a drug called NONO-2 and a delivery system called MUSA. Guided by Martin Gestler, a hard-charging expert on biotechnology start-up companies, she has left academic research to found a company called SURYA. The extract describes the preparation and launch of the fledgling company ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Carl Djerassi

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo